Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Peripheral T-cell lymphomas (PTCLs) are aggressive cancers with poor prognoses.
• Histone deacetylase inhibitors (HDACis) are emerging as a therapeutic option for PTCLs.
• HDACis demonstrate efficacy in relapsed or refractory PTCL cases.

Purpose of the Study:

• To review the effectiveness of HDACis in treating PTCL.
• To explore the mechanisms of action of HDACis in PTCL.
• To discuss the clinical and real-world evidence supporting HDACis in PTCL management.

Main Methods:

• Review of clinical trial data and real-world evidence on HDACis for PTCL.
• Analysis of studies investigating the anti-tumor effects of HDACis.
• Examination of gene expression profile studies related to HDACis' mechanism of action.

Main Results:

• HDACis, including romidepsin and belinostat, show efficacy in PTCL, yielding durable responses.
• HDACis induce anti-tumor effects by regulating gene expression, leading to cell cycle arrest and apoptosis.
• Real-world data support HDACis as a beneficial treatment choice for PTCL.

Conclusions:

• HDACis represent a significant therapeutic advance for PTCL patients.
• Despite positive outcomes, HDACis do not cure most PTCL patients.
• Further investigation into novel combinations and targeted agents is warranted for PTCL treatment.